01—Abstract
Summary
Summary of the 6-K filed April 28, 2025. Cited figures are marked; the original filing is the authoritative source.
James Hardie Industries plc (ASX / NYSE: JHX) furnished a Form 6-K on April 28, 2025, attaching a letter to shareholders that sets out the Board's public position on corporate governance in connection with the proposed transaction with AZEK.
The Board states that it has maintained governance practices aligned with the ASX Corporate Governance Council's Principles and Recommendations (4th Edition) and NYSE listing standards, and that these commitments will not change after the AZEK transaction is completed. On board composition, the letter says the Board's Board Charter requires a majority of independent directors and an independent Chair, and that these requirements are not changing. Upon completion, two of the three directors added from AZEK will be independent, and the only non-independent directors will be the CEO and the then former AZEK CEO.
Anne Lloyd, an independent director, will remain Chair. On shareholder rights, the Board says it will continue to hold an annual advisory vote on the remuneration report, has no intention to seek ASX Foreign Exempt Listing status, and would hold a shareholder vote before any decision to change its ASX listing status.
On management pay, the letter says remuneration will continue to link to shareholder value through performance criteria such as ROCE, plus new metrics tied to the combined company, including achievement of cost and commercial synergies within expected timeframes. The filing also cautions that the transaction may not be completed as described or at all, and identifies risks including regulatory approvals, AZEK stockholder approval, additional indebtedness, synergy realization, integration costs, and the possible loss of foreign private issuer status.
02—Key points
Key Highlights
- The Board commits to keeping an independent Chair (Anne Lloyd, who will remain Chair) and a majority of independent directors after the AZEK transaction.
- Upon completion, two of the three directors added from AZEK will be independent; the only non-independent directors will be the CEO and the then former AZEK CEO.
- The Board states it is not seeking ASX Foreign Exempt Listing status and would hold a shareholder vote before any decision to change its ASX listing status.
- The annual advisory vote on the Remuneration Report will continue, a practice the company says it has followed voluntarily since 2005.
- Management remuneration will add performance metrics tied to the combined company, including achievement of cost and commercial synergies in expected timeframes, alongside ROCE.
- The ASX listing rule LR 10.14 requirement for shareholder approval of equity issued to directors, including management directors, will continue after the transaction.
- Forward-looking risks flagged include regulatory and AZEK stockholder approvals, additional indebtedness, synergy realization, integration costs, and possible loss of foreign private issuer status.
03—Questions
Frequently Asked Questions
Will James Hardie keep an independent board chair and majority-independent board after the AZEK transaction?
Yes. The letter states that the Board Charter requires a majority of independent directors and an independent Chair, that these requirements are not changing, and that Anne Lloyd, an independent director, will remain Chair.
How will the board's independence change once the AZEK transaction closes?
The filing says two of the three directors added from AZEK will be independent. The only non-independent directors will be the CEO and the then former AZEK CEO.
Will shareholders get a say on any change to the company's ASX listing status?
Yes. The Board says it has no intention to seek ASX Foreign Exempt Listing status and would hold a shareholder vote before making any decision to change its ASX listing status.
How will executive pay be tied to the combined company's performance?
The letter says performance criteria will continue to include metrics such as ROCE, and will add metrics reflecting the combined company, such as achievement of cost and commercial synergies in expected timeframes. Details will be provided in the annual Remuneration Report.
What could prevent the AZEK transaction from being completed as described?
The cautionary statement lists risks including failure to obtain regulatory approvals or AZEK stockholder approval, uncertain access to financing, the impact of additional indebtedness, possible failure to realize synergies, integration costs, transaction-related litigation, and the possibility that James Hardie could lose its foreign private issuer status. The filing says there can be no assurance the transaction will be consummated as described or at all.
04—Continue